Literature DB >> 24288008

A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms.

Rolando Perez-Lorenzo1, Kamraan Z Gill2, Che-Hung Shen3, Feng X Zhao1, Bin Zheng3, Hans-Joachim Schulze4, David N Silvers1, Georg Brunner5, Basil A Horst6.   

Abstract

The phosphoinositide-3 kinase (PI3K) pathway is deregulated in a significant proportion of melanomas, and PI3K pathway activation in combination with constitutively active mitogen-activated protein kinase signaling shows synergistic effects in the process of melanoma tumorigenesis. Recently, a tumor suppressor function for the lipid phosphatase inositol polyphosphate 4-phosphatase type II (INPP4B) has been described in breast and prostate cancers, with impact on PI3K signaling output. Given the importance of PI3K pathway activity for melanoma formation and growth, we aimed to assess the role of INPP4B in melanocytic tumors. Our studies in native tumors suggest that decreased INPP4B expression is an event correlating with tumor progression in melanocytic neoplasms. We further demonstrate that INPP4B regulates PI3K/Akt signaling and exerts a tumor suppressor effect, impacting the proliferative, invasive, and tumorigenic capacity of melanoma cells. INPP4B expression in melanocytic neoplasms may therefore have potential as a biomarker for disease progression and as a modulator for the prediction of treatment outcome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24288008     DOI: 10.1038/jid.2013.511

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  36 in total

1.  A genetic screen for candidate tumor suppressors identifies REST.

Authors:  Thomas F Westbrook; Eric S Martin; Michael R Schlabach; Yumei Leng; Anthony C Liang; Bin Feng; Jean J Zhao; Thomas M Roberts; Gail Mandel; Gregory J Hannon; Ronald A Depinho; Lynda Chin; Stephen J Elledge
Journal:  Cell       Date:  2005-06-17       Impact factor: 41.582

2.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

3.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Authors:  Vikas K Goel; Alexander J F Lazar; Carla L Warneke; Mark S Redston; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2006-01       Impact factor: 8.551

4.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

Review 5.  Melanoma: new insights and new therapies.

Authors:  Vasiliki A Nikolaou; Alexander J Stratigos; Keith T Flaherty; Hensin Tsao
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

6.  Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.

Authors:  Derek L Dai; Magdalena Martinka; Gang Li
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

7.  The lipid phosphatase SHIP2 controls insulin sensitivity.

Authors:  S Clément; U Krause; F Desmedt; J F Tanti; J Behrends; X Pesesse; T Sasaki; J Penninger; M Doherty; W Malaisse; J E Dumont; Y Le Marchand-Brustel; C Erneux; L Hue; S Schurmans
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

8.  Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.

Authors:  H Tsao; X Zhang; K Fowlkes; F G Haluska
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

9.  Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.

Authors:  C Nogueira; K-H Kim; H Sung; K H T Paraiso; J-H Dannenberg; M Bosenberg; L Chin; M Kim
Journal:  Oncogene       Date:  2010-08-16       Impact factor: 9.867

Review 10.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

View more
  22 in total

1.  Expression and transcriptional profiling of the LKB1 tumor suppressor in cervical cancer cells.

Authors:  Xiaoli Zhang; Hanxiang Chen; Xiao Wang; Weiming Zhao; Jason J Chen
Journal:  Gynecol Oncol       Date:  2014-05-02       Impact factor: 5.482

2.  Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.

Authors:  Muhan Chen; Dawid G Nowak; Lloyd C Trotman
Journal:  Clin Cancer Res       Date:  2014-06-15       Impact factor: 12.531

3.  Single-cell gene expression signatures reveal melanoma cell heterogeneity.

Authors:  M Ennen; C Keime; D Kobi; G Mengus; D Lipsker; C Thibault-Carpentier; I Davidson
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

4.  INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.

Authors:  I Dzneladze; R He; J F Woolley; M H Son; M H Sharobim; S A Greenberg; M Gabra; C Langlois; A Rashid; A Hakem; N Ibrahimova; A Arruda; B Löwenberg; P J M Valk; M D Minden; L Salmena
Journal:  Leukemia       Date:  2015-03-04       Impact factor: 11.528

5.  In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.

Authors:  Chen Li Chew; Andrea Lunardi; Federico Gulluni; Daniel T Ruan; Ming Chen; Leonardo Salmena; Michiya Nishino; Antonella Papa; Christopher Ng; Jacqueline Fung; John G Clohessy; Junko Sasaki; Takehiko Sasaki; Roderick T Bronson; Emilio Hirsch; Pier Paolo Pandolfi
Journal:  Cancer Discov       Date:  2015-04-16       Impact factor: 39.397

6.  PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.

Authors:  Jillian M Silva; Marian M Deuker; Bruce C Baguley; Martin McMahon
Journal:  Pigment Cell Melanoma Res       Date:  2017-04-20       Impact factor: 4.693

7.  BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.

Authors:  Jillian M Silva; Christina Bulman; Martin McMahon
Journal:  Mol Cancer Res       Date:  2014-01-14       Impact factor: 5.852

8.  INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT.

Authors:  Shuyu Zhai; Yuanbin Liu; Xiongxiong Lu; Hao Qian; Xiaomei Tang; Xi Cheng; Yue Wang; Yusheng Shi; Xiaxing Deng
Journal:  Onco Targets Ther       Date:  2019-10-09       Impact factor: 4.147

9.  Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.

Authors:  Mayanne M T Zhu; Samantha Burugu; Dongxia Gao; Jamie Yu; Zuzana Kos; Samuel Leung; Basil A Horst; Torsten O Nielsen
Journal:  Mod Pathol       Date:  2020-04-29       Impact factor: 7.842

10.  INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer.

Authors:  Samuel J Rodgers; Lisa M Ooms; Viola M J Oorschot; Ralf B Schittenhelm; Elizabeth V Nguyen; Sabryn A Hamila; Natalie Rynkiewicz; Rajendra Gurung; Matthew J Eramo; Absorn Sriratana; Clare G Fedele; Franco Caramia; Sherene Loi; Genevieve Kerr; Helen E Abud; Georg Ramm; Antonella Papa; Andrew M Ellisdon; Roger J Daly; Catriona A McLean; Christina A Mitchell
Journal:  Nat Commun       Date:  2021-05-25       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.